Who are Trifluridine cures's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Suvemcitug injection, trifluridine/tipiracil tablets, TS-1, oxaliplatin, Fluoropyrimidine-based Chemotherapy, Carac® (Fluorouracil) Cream, CAPEOX/Capecitabine, Pifeltro.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/trifluridine-cures.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Trifluridine cures — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trifluridine cures (Trifluridine cures) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside analog; antimetabolite. Area: Oncology.

phase 3 Nucleoside analog; antimetabolite Thymidylate synthase; DNA Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Trifluridine cures (Trifluridine cures) — Centre Hospitalier Universitaire Dijon. Trifluridine is a nucleoside analog that inhibits thymidylate synthase and gets incorporated into DNA, disrupting cancer cell replication.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Trifluridine cures TARGET	Trifluridine cures	Centre Hospitalier Universitaire Dijon	phase 3	Nucleoside analog; antimetabolite	Thymidylate synthase; DNA
Suvemcitug injection, trifluridine/tipiracil tablets	Suvemcitug injection, trifluridine/tipiracil tablets	Jiangsu Simcere Pharmaceutical Co., Ltd.	phase 3	Nucleoside analog; antimetabolite	Thymidylate synthase; DNA
TS-1, oxaliplatin	TS-1, oxaliplatin	Samsung Medical Center	phase 3	Fluoropyrimidine + platinum-based chemotherapy combination	Thymidylate synthase; DNA (platinum crosslinking)
Fluoropyrimidine-based Chemotherapy	Fluoropyrimidine-based Chemotherapy	Hoffmann-La Roche	phase 3	Antimetabolite chemotherapy	Thymidylate synthase; DNA/RNA incorporation
Carac® (Fluorouracil) Cream	Carac® (Fluorouracil) Cream	Actavis Inc.	phase 3	Antimetabolite; Pyrimidine analog	Thymidylate synthase; DNA and RNA synthesis
CAPEOX/Capecitabine	CAPEOX/Capecitabine	Qilu Pharmaceutical Co., Ltd.	phase 3	Antimetabolite; Fluoropyrimidine	Thymidylate synthase; DNA/RNA synthesis
Pifeltro	DORAVIRINE	Merck & Co.	marketed	Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]		2018-01-01

Recent regulatory actions (last 90 days)

2026-04-20 — Pifeltro · FDA · approved · US · Merck & Co.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside analog; antimetabolite class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Astellas Pharma Global Development, Inc. · 1 drug in this class
AstraZeneca · 1 drug in this class
Celgene · 1 drug in this class
Centre Hospitalier Universitaire Dijon · 1 drug in this class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · 1 drug in this class
Eisai Inc. · 1 drug in this class
Gruppo Italiano Malattie EMatologiche dell'Adulto · 1 drug in this class
Jiangsu Simcere Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Trifluridine cures — Competitive Intelligence Brief. https://druglandscape.com/ci/trifluridine-cures. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing